Clinical trial: NCT02229084
Section: Alternatives
Subsections: Are There Benefits To Taking Part In The Research?|What Other Choices Do I Have If I Do Not Take Part In This Research?

Taking part in this research may or may not directly benefit your health. While doctors hope a breast cancer vaccine will be more useful against breast cancer as compared to the usual treatment, there is no proof of this yet. We do know that the information from this research will help doctors learn more about breast cancer treatment. This information could help future breast cancer patients. UAMS and HOG cannot and do not guarantee you will benefit if you take part in this study. The research drug you receive may even be harmful. You have the right to refuse to participate in this study.

Your other choices may include:
Chemotherapy or hormonal therapy as standard treatment or care for your cancer without the vaccine.  
Taking part in another study. No treatment
Talk to your doctor about your choices before you decide if you will take part in this research.
Clinical trial: NCT02229084
Section: Confidentiality
Subsections: Will My Medical Information Be Kept Private?

We will do our best to make sure that the personal information in your medical record will be kept private. However, we cannot guarantee total privacy. Your personal information may be given out if required by law. We may share your de-identified study information with other researchers outside of UAMS, and we may publish our findings or present them at scientific meetings. However, if information from this study is published, presented at scientific meetings, or shared for reanalysis with other researchers, your name and other personal information will not be used.  
Participants will be identified by study numbers only on all research documents. The connection with the participants name will be kept by research personnel in a locked facility. UAMS shall retain the records and reports for 2 years after a marketing application is approved for the drug; or, if an application is not approved for the drug, until 2 years after shipment and delivery of the drug for investigational use is discontinued and FDA has been so notified. After such time all study records will be destroyed as well as the links between identifiers of the research participants and their research study numbers, unless you give us permission to store your study information for future research. Authorized representatives from many organizations are eligible to review your medical records, including information that identifies you, as part of their responsibilities to protect human participants in research, and to conduct quality assurance, safety and data analysis. These organizations include:  
Winthrop P. Rockefeller Cancer Institute (WPRCI) Food and Drug Administration (FDA)
National Cancer Institute (NCI)
Office for Human Research Protections (OHRP) UAMS Institutional Review Board (IRB)
UAMS Office of Research Compliance (ORC)
UAMS Office of Research Regulatory Affairs (ORRA) Other institutional oversight offices
Authorized representatives from these agencies may need to review your records and may see your name. They are bound by rules of confidentiality not to reveal your identity to others. In the future, it is possible that we may share your coded (de-identified) genetic testing results with other researchers in an controlled-access national database, so that other investigators can use them for research. This means that only researchers who apply for and get permission to use the information for a specific research project will be able to access the information. We would use a code number instead of your name, address, or identifying information. This is done to confirm results from studies like ours and to allow for more rapid discoveries. There is a risk that someone could trace the information in a central database back to you. Even without your name or other identifiers, your genetic information is unique to you. The researchers believe the chance that someone will identify you is small, because your samples will be coded (without your name or identifying information), but the risk may change in the future as people come up with new ways of tracing information.  
By law, the study team must release certain information to the appropriate authorities if at any  
 time during the study there is concern that abuse has possibly occurred or you disclose a desire to harm yourself or others.  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.
Clinical trial: NCT02229084
Section: Duration of Study Involvement
Subsections: How Many People Will Take Part In Research?|Week 1|Weeks 7, 10, & 13|Week 4|How Long Will I Be In The Research?

We will screen up to 81 women in order to enroll up to 61 women, ages 18 and older with breast cancer from two sites in Arkansas: the University of Arkansas for Medical Sciences (UAMS) and Highlands Oncology Group (HOG). It is possible that up to 61 women are enrolled at either site but the total combined enrollment for both sites will not be more than 61. At the beginning of the research, women were enrolled in groups of 5 to determine when the vaccine should be given in relation to the chemotherapy schedule. The timing of the vaccination relative to chemotherapy will be evaluated to see which schedule had the best immune response with the least harmful side effects. This part of the research, which involved 25 research participants, has been completed. Using the schedule determined to be the best, up to 36 additional women will now be enrolled to evaluate the effect of the vaccine and chemotherapy on the cancer.

Urine pregnancy test for women who are able to have children Administer vaccine Review of side effects Clinic visit for history and physical examination Blood work for research

AC Chemotherapy - cyclophosphamide 600 mg/m2 and doxorubicin 60 mg/m2(doses may be reduced)
Growth factor may be given at physician's discretion Review of side effects Clinic visit for history and physical examination Routine blood work Blood work for research Week 16  
  
  
Docetaxel 75 mg/m2(dose may be reduced or replaced with Paclitaxel 175 mg/m2)
Growth factor may be given at physician's discretion Review of side effects Clinic visit for history and physical examination Routine blood work Blood work for research

AC Chemotherapy - cyclophosphamide 600 mg/m2 and doxorubicin 60 mg/m2(doses may be reduced)
Growth factor may be given at physician's discretion Review of side effects Clinic visit for history and physical exam Routine blood work  
Weeks 19 & 22 Docetaxel 75 mg/m2(dose may be reduced or replaced with Paclitaxel 175 mg/m2)
Growth factor may be given at physician's discretion Review of side effects Clinic visit for history and physical examination Routine blood work Week 25 Docetaxel 75 mg/m2(dose may be reduced or replaced with Paclitaxel 175 mg/m2)
Growth factor may be given at physician's discretion Review of side effects Clinic visit for history and physical examination Routine blood work Blood work for research

The approximate length of complete study participation will be around 18 months. You will be treated with the vaccine for 3 doses within 3 weeks. If you have significant side effects or problems related to the vaccine, the remaining doses will not be given and you may be removed from the study. If you discontinue the vaccine early, your visits will remain the same as listed above including collection of blood work for research.
Clinical trial: NCT02229084
Section: Participant Responsibilities
Subsections: Before You Begin The Research:

You will need to have the following exams, tests or procedures to find out if you can participate in the research study. Most of these exams, tests or procedures are part of regular cancer care and will be done even if you do not join the research. If you have had some of them recently, they may not need to be repeated. This will be up to your research doctor.
Clinical trial: NCT02229084
Section: Participant's Rights
Subsections: What Are My Rights If I Take Part In This Research?

Taking part in this research is your choice. You may choose either to take part or not to take part in the research. If you decide to take part in this study, you may leave the study at any time. No matter what decision you make, there will be no penalty to you and you will not lose any of your regular benefits. Your relationship with your doctor or with UAMS will not be affected by not participating or leaving the research. Leaving the research will not affect your medical care. You can still get your medical care from our institution.  
We will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study. We will tell you of any new findings (good or bad) in the research or new alternatives to participation that may cause you to change your mind about continuing in the research. If new information is provided to you, your consent will be re-obtained. You may also request the results of the research from your research doctor after all the analyses are completed.  
In the case of injury resulting from this study, you do not lose any of your legal rights to seek payment by signing this form.
Clinical trial: NCT02229084
Section: Possible Risks, Discomforts, and Inconveniences
Subsections: What Side Effects Or Risks Can I Expect From Being In The Research?|Risks And Side Effects Related To The Vaccine: Likely|Rare But Serious|Risks And Side Effects Related To Montanide™ Isa 51 Vg:|Reproductive Risks|Other Risks|Genetic Testing Risks|What If I Am Injured While Participating In This Research?

You may have side effects while on the research. Everyone taking part in the study will be watched carefully for any side effects. However, doctors don't know all the side effects that may happen. Side effects may be mild or very serious. Your health care team may give you medicines to help lessen side effects. Many side effects go away once you stop taking the vaccine. In some cases, side effects can be serious, long lasting, or may never go away. You should talk to your research doctor about any side effects that you have while taking part in the research. If you have significant side effects or problems related to the chemotherapy, the remaining doses may be delayed, reduced, replaced or discontinued if the research doctor believes it is in your best interest. In general, the risks and side effects are lower than standard chemotherapy treatments and the blood draws are similar in the quantity of blood taken and the frequency of the tests.

Localized itching, redness, stinging at the site of the injection of the vaccine A decrease in energy Temporary swelling, tenderness of the glands (lymph nodes)
Discomfort from needles used for blood work

Severe allergic reactions (anaphylaxis) can result in shock and even death Over activation of your immune system Guillain-Barre Syndrome: a condition resulting in severe weakness to the point of not being able to walk or breathe. In extreme cases, it can require a breathing machine. It can be treated and most people recover.

Redness of the skin, rash, itching  
  
Diarrhea, loss of appetite, nausea, vomiting, abnormal taste Confusion Tingling or burning sensation Shortness of breath, chest pain High blood pressure, irregular heartbeat, chest pain Headache, joint pain, bone pain, abdominal pain, muscle pain Fever Flu-like syndrome (chills, achiness) Fatigue

You should not become pregnant or have a baby while on this study and for 18 months after the last dose of the vaccine because the vaccine in this study may affect an unborn baby. Women should not breastfeed a baby while on this study. It is important you understand that you need to use birth control while on this study. Check with your study doctor about what kind of birth control methods to use and how long to use them. It is not known how the vaccine would affect an unborn baby. If you or your partner should become pregnant while participating in the study or within 18 months of study participation, notify your physician.

Identification of previously unknown conditions during collection of medical history, physical exam assessment, or blood draw laboratory results.  
Possible breach of privacy and confidentiality. Participants will be identified by study numbers only on all research documents to minimalize the risk of a privacy and/or confidentiality breach. Research records will be stored in a locked area with access to study personnel only.

With genetic testing of your tissue, there is a potential risk of loss of confidentiality. Every effort will be made to protect your confidential information, but this cannot be guaranteed. The genetic information obtained as a result of your participation in this research will not be included in your medical record. Information from which you may be personally identified will be maintained in a confidential, secure location in the Breast Cancer Vaccine Research Laboratory, accessible only by authorized members of the study team, and will not be disclosed to third parties except as described in this consent form, with your permission, or as may be required by law.  
Genetic testing involves unique risks such as psychological and social risks and the risk of reidentification. Social risks include being stigmatized, discriminated against, labeled, or having difficulty obtaining employment or insurance. Some of your genetic information may be sent to other scientific or commercial databases, such as one maintained by the National Institutes of Health, for other researchers to use. This information would include a code number instead of your name. There is a risk that someone could trace the information back to you. Even without your name or other identifiers, your genetic information is unique to you. We believe the chance that someone will identify you is very small, because your samples will be coded (without your name or identifying information), but the risk may change in the future as people come up with new ways of tracing information. The genetic testing will be done for research purposes only, and we do not plan to return any results to you or your doctor. The Genetic Information Nondiscrimination Act (GINA) is a Federal law that will protect you in the  
  
following ways:
Health insurance companies and group plans may not request genetic information from this research; Health insurance companies and group plans may not use your genetic information when making decisions regarding your eligibility or premiums;  
Employers with 15 or more employees may not use your genetic information when making a decision to hire, promote, or fire you or when setting the terms of your employment.  
GINA does not protect you against genetic discrimination by companies that sell life insurance, disability insurance, or long-term care insurance. GINA also does not protect you against discrimination based on an already-diagnosed genetic condition or disease.

In the event you are hurt by being in this research, treatment will be available. This treatment may include: first aid, emergency treatment, and/or follow-up care. This treatment may be billed to you or your insurance company in the normal manner. There is no guarantee that your insurance company will agree to cover those charges. Normally, no other form of compensation is available.  
If you think you have been hurt by this research or if you have any questions about this medical care, let the study investigator know right away by calling Dr. Sindhu Malapati, at (501) 686-8530. After hours, you may reach Dr. Malapati by digital pager at (501) 405-9707 or the medical oncology physician on call at UAMS at (501) 686-8530. Any suspected side effects must be brought to the attention of your physician immediately.
Clinical trial: NCT02229084
Section: Procedures
Subsections: What Is Involved In This Research?|Summary Of Tests To Be Done Prior To The Study: Standard Medical Care For Cancer Treatments:|Summary Of Tests To Be Done During The Clinical Trial:|Breakdown Of Study Visits:

Your participation in this research is voluntary. If you refuse to participate in this research, you will not be penalized in any way and you will not lose any benefits to which you are otherwise entitled. If you choose to participate in this research, but then change your mind, you can stop participating in the research and you will not be penalized or lose any benefits.

History and physical exam Blood work for blood counts, liver and kidney function, and calcium level Urine pregnancy test if you are able to have children
The total amount of blood that will be taken for standard medical care prior to the study is one  
 and a half teaspoons.

If the exams, tests and procedures show that you can be in the research, and you choose to take part, then you will need the following tests and procedures at different times throughout the study.  
These are standard for patients undergoing cancer treatments:
Blood work for blood counts, liver and kidney function, and calcium level Medical history and physical exams Chemotherapy You will need the following tests and procedures that are either being tested in this research or are being done to see how the research is affecting your body:
Blood work for research to check the reaction of the immune system Notations of side effects and medications you are taking Investigational vaccine
During this study, you will be asked to provide eight blood samples for research. Up to 100mL (approximately seven tablespoons) of blood will be collected each time "Blood work for research" is listed in the breakdown of study visits below. These samples will be used to determine the effect of the vaccine on your immune system. Any leftover samples will be discarded, unless you give us permission to save them for future research.  
We would like to collect leftover archival breast tissue samples from tissue collected as part of standard biopsy and/or surgery. Your doctor will not take any more tissue during biopsy and/or surgery than is needed for your care. These samples will be used to look at and examine the tissue and the effect of the vaccine on the tissue.  
To examine the effect of the vaccine on your immune system and tissue, we may test your blood and tumor samples for immune and tumor cell gene expression (genetic information about how cells behave) or methylation (epigenetic information about changes in genes that turn them "on" or "off").

You will receive subcutaneous (SC) injections, or a shot given under the skin, of the vaccine at  
  
Weeks 1, 2, and 3 for a total of 3 doses. The shots will be given to you at different places on your abdomen. The visit breakdown below will give you a detailed description of everything that will happen while participating in this study.  
This breakdown includes standard chemotherapy, growth factor (to stimulate growth of healthy white blood cells), and surgery, which are part of standard care. The chemotherapy, growth factor, and surgery are not being tested as part of this study, just your response to the vaccine. Your research visits will be combined with your regularly scheduled clinic visits, with the exception of the visits for weeks 1, 2 and 3. These visits are just for research. Research blood samples will be collected eight times during the study.
Clinical trial: NCT02229084
Section: Purpose of Research
Subsections: Why Is This Research Being Done?

The purpose of this research is to evaluate a new experimental breast cancer vaccine (used to  
 stimulate immune cell production) with chemotherapy and then surgery. This study will help us learn if the vaccine is safe and whether your body responds to the vaccine. We will also see if the vaccine helps to improve the effectiveness of the chemotherapy for treating your cancer. There are no commercially available breast cancer vaccines at this time. There are other breast cancer vaccine trials at other institutions but no other breast cancer vaccine trials are now available in Arkansas.
Clinical trial: NCT02229084
Section: Withdrawal from Study
Subsections: What Happens When I Am Finished Taking The Vaccine?|Can I Stop Being In The Research?

The research lasts for approximately 73 weeks (about one year and six months). You will continue your standard treatments and follow-ups for breast cancer after completing the study. You should avoid becoming pregnant for at least 18 months after participation in the study (see additional information about pregnancy risks in the "Reproductive Risks" section). To avoid becoming pregnant, you should either abstain from sexual activity or practice a method of birth control. Except for surgical removal of the uterus, tubal ligation, and abstinence, birth control methods such as oral contraceptives (birth control pills), barrier method, and IUDs (implanted device) are not totally effective in preventing pregnancy.

Yes. You can decide to stop at any time. Contact the research doctor if you are thinking about stopping or decide to stop. He or she will tell you how to stop safely. It is important to tell the research doctor if you are thinking about stopping so any risks from the vaccine can be evaluated by your doctor. Another reason to tell your doctor that you are thinking about stopping is to discuss what follow up care and testing could be most helpful for you.  
The research doctor may stop you from taking part in this study at any time if he/she believes it is in your best interest; if you do not follow the study rules; or if the study is stopped. This may happen without your consent. If there is new information from the research concerning side effects or new information about  
 alternate treatments, which may benefit you, you will be informed by your research doctor.  
If you withdraw from the study, any information collected before you withdraw will be retained in the study. If blood samples are collected and you withdraw from the research, we will discard your samples.